Hasil Pencarian - Israel Lowy

  • Menampilkan 1 - 12 hasil dari 12
Perbaiki Hasil
  1. 1
    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

    Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 oleh Rom Leidner, Carlo Bifulco, Israel Lowy, Gerald S. Falchook, Elizabeth Stankevich, Brian Piening, Matthew G. Fury

    Diterbitkan 2016-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.

    An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. oleh Elizabeth Colston, Dennis Grasela, David Gardiner, R Pat Bucy, Blisse Vakkalagadda, Alan J Korman, Israel Lowy

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy

    Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy oleh C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer Frytak, Israel Lowy, Matthew G. Fury

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

    535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors oleh Israel Lowy, Roman Groisberg, Nehal Lakhani, Melissa Mathias, Siyu Li, Melissa Johnson, Frank Seebach, Matthew Fury, Hyunsil Han, Kerry Casey, Dimitris Skokos

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    264 Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma

    264 Correlation of virus-specific CD8+ T cells to clinical response following treatment with Pexa-Vec and Cemiplimab in patients with advanced renal cell carcinoma oleh Gavin Thurston, Israel Lowy, Vladimir Jankovic, Myles Dillon, Lianjie Li, Jeongsook Bang, Nicholas Gaspar, Jessica Kuhnert, Nathalie Fiaschi, Glenn Kroog, Kyoung Soo Ha, Raquel Deering

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Tumor-reprogrammed resident T cells resist radiation to control tumors

    Tumor-reprogrammed resident T cells resist radiation to control tumors oleh Ainhoa Arina, Michael Beckett, Christian Fernandez, Wenxin Zheng, Sean Pitroda, Steven J. Chmura, Jason J. Luke, Martin Forde, Yuzhu Hou, Byron Burnette, Helena Mauceri, Israel Lowy, Tasha Sims, Nikolai Khodarev, Yang-Xin Fu, Ralph R. Weichselbaum

    Diterbitkan 2019-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

    A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma oleh Robert G. Maki, Achim A. Jungbluth, Sacha Gnjatic, Gary K. Schwartz, David R. D’Adamo, Mary Louise Keohan, Michael J. Wagner, Kelly Scheu, Rita Chiu, Erika Ritter, Jennifer Kachel, Israel Lowy, Lloyd J. Old, Gerd Ritter

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.

    A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus... oleh David Gardiner, Jay Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K Rajender Reddy, Kyong-Mi Chang, Mark Sulkowski, Steven O' Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind-Rotolo, Dennis Grasela, Mark Selby, Alan J Korman, Israel Lowy

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

    Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis oleh Dirk Schadendorf, Chieh-I Chen, Zhen Chen, Israel Lowy, Elizabeth Stankevich, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Anne Lynn S Chang, Emmanuel Okoye, Jocelyn Booth, Siyu Li, Matthew G Fury, Alexander Guminski, Medha Sasane, Alesha A Thai, Suk-Young Yoo, Vera Mastey

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

    Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer oleh Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

    428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) oleh Marcus Butler, Rogerio Neves, Lisa Licitra, Israel Lowy, Zeynep Eroglu, Karl Lewis, Leonel Hernandez-Aya, Axel Hauschild, Emmanuel Okoye, Siyu Li, Jean-Francois Baurain, Oliver Bechter, Ketty Peris, Aleksandar Sekulic, Alexander Stratigos, Lara Dunn, Anne Lynn Chang, Michael Migden, Kosalai Mohan, Ebony Coates, Emily Ruiz, Frank Seebach, David Weinreich, George Yancopoulos, Timothy Bowler, Matthew Fury

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

    High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma oleh Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: